Message #28 From:
Stock News Bot Date: July 24, 2006 06:00:00 AM
EVSC News Endovasc President & CEO Featured in Exclusive Interview with WallSt.net
HOUSTON--(BUSINESS WIRE)--July 24, 2006--Endovasc Inc. (OTCBB: EVSC), announced that the Company's President and CEO, Dr. Diane Dottavio, was featured in an exclusive interview with WallSt.net on Thursday, July 20, 2006. WallSt.net is a professional forum for the financial community, primarily known for interviews with CEO's and prominent business executives.
Topics covered during the interview include the Company's upcoming Phase IIIa trial of its leading drug candidate, Liprostin, for the treatment of Peripheral Arterial Disease (PAD), current market conditions for drugs treating these conditions, the company's nutraceutical technology incorporated in the product Endothil-CR, and both short and long-term strategic objectives for the Company.
To hear the interview in its entirety, visit www.wallst.net and click on "Interviews." Interviews require free registration, and can be accessed either by locating the respective company's ticker symbol under the appropriate exchange on the left-hand column of the "Interviews" section of the site, or by entering the respective company's ticker symbol in the Search Archive window.
About Endovasc, Inc.
Endovasc, Inc is focused on developing and commercializing drug candidates in the areas of cardiovascular and metabolic medicine. Endovasc is organized as a business development company, operating through the following subsidiaries: Liprostin Inc., which holds the intellectual property for a liposomal based treatment to increase circulation and reduce leg pain in patients suffering from vascular disease; Prostent, Inc., which is developing urinary tract stent coating technology; and Nutraceutical Development Corporation.
For more information about Endovasc, please visit www.endovasc.com.
Safe Harbor:
Except for the historical information contained herein, this news release contains forward-looking statements that involve risk and uncertainties, including clinical results, the timely availability and acceptance of new products, the impact of competitive products and pricing, the availability of funding from partners or capital markets, and the management of growth, as well as the other risks detailed from time to time in Endovasc's Exchange Commission (SEC) Filings, including the company's Annual Report on Form 10-KSB, and quarterly reports on Form 10-QSB.
